The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Research Report 2025
Synopsis
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months.
The global Rx Irritable Bowel Syndrome (IBS) Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Rx Irritable Bowel Syndrome (IBS) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rx Irritable Bowel Syndrome (IBS) Drugs.
Report Scope
The Rx Irritable Bowel Syndrome (IBS) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rx Irritable Bowel Syndrome (IBS) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rx Irritable Bowel Syndrome (IBS) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ironwood Pharmaceuticals
Bausch Health
Takeda
Sebela Pharmaceuticals
Allergan
Segment by Type
IBS-D Drugs
IBS-C Drugs
Others
Segment by Application
Women
Men
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rx Irritable Bowel Syndrome (IBS) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months.
The global Rx Irritable Bowel Syndrome (IBS) Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Rx Irritable Bowel Syndrome (IBS) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rx Irritable Bowel Syndrome (IBS) Drugs.
Report Scope
The Rx Irritable Bowel Syndrome (IBS) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rx Irritable Bowel Syndrome (IBS) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rx Irritable Bowel Syndrome (IBS) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ironwood Pharmaceuticals
Bausch Health
Takeda
Sebela Pharmaceuticals
Allergan
Segment by Type
IBS-D Drugs
IBS-C Drugs
Others
Segment by Application
Women
Men
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rx Irritable Bowel Syndrome (IBS) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 IBS-D Drugs
1.2.3 IBS-C Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Women
1.3.3 Men
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Perspective (2019-2030)
2.2 Rx Irritable Bowel Syndrome (IBS) Drugs Growth Trends by Region
2.2.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Rx Irritable Bowel Syndrome (IBS) Drugs Historic Market Size by Region (2019-2024)
2.2.3 Rx Irritable Bowel Syndrome (IBS) Drugs Forecasted Market Size by Region (2025-2030)
2.3 Rx Irritable Bowel Syndrome (IBS) Drugs Market Dynamics
2.3.1 Rx Irritable Bowel Syndrome (IBS) Drugs Industry Trends
2.3.2 Rx Irritable Bowel Syndrome (IBS) Drugs Market Drivers
2.3.3 Rx Irritable Bowel Syndrome (IBS) Drugs Market Challenges
2.3.4 Rx Irritable Bowel Syndrome (IBS) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Rx Irritable Bowel Syndrome (IBS) Drugs Players by Revenue
3.1.1 Global Top Rx Irritable Bowel Syndrome (IBS) Drugs Players by Revenue (2019-2024)
3.1.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Rx Irritable Bowel Syndrome (IBS) Drugs Revenue
3.4 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Concentration Ratio
3.4.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Rx Irritable Bowel Syndrome (IBS) Drugs Revenue in 2023
3.5 Rx Irritable Bowel Syndrome (IBS) Drugs Key Players Head office and Area Served
3.6 Key Players Rx Irritable Bowel Syndrome (IBS) Drugs Product Solution and Service
3.7 Date of Enter into Rx Irritable Bowel Syndrome (IBS) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Rx Irritable Bowel Syndrome (IBS) Drugs Breakdown Data by Type
4.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Historic Market Size by Type (2019-2024)
4.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Forecasted Market Size by Type (2025-2030)
5 Rx Irritable Bowel Syndrome (IBS) Drugs Breakdown Data by Application
5.1 Global Rx Irritable Bowel Syndrome (IBS) Drugs Historic Market Size by Application (2019-2024)
5.2 Global Rx Irritable Bowel Syndrome (IBS) Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size (2019-2030)
6.2 North America Rx Irritable Bowel Syndrome (IBS) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2019-2024)
6.4 North America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Market Size (2019-2030)
7.2 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2019-2024)
7.4 Europe Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs Market Size (2019-2030)
8.2 Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size (2019-2030)
9.2 Latin America Rx Irritable Bowel Syndrome (IBS) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2019-2024)
9.4 Latin America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs Market Size (2019-2030)
10.2 Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ironwood Pharmaceuticals
11.1.1 Ironwood Pharmaceuticals Company Detail
11.1.2 Ironwood Pharmaceuticals Business Overview
11.1.3 Ironwood Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Introduction
11.1.4 Ironwood Pharmaceuticals Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024)
11.1.5 Ironwood Pharmaceuticals Recent Development
11.2 Bausch Health
11.2.1 Bausch Health Company Detail
11.2.2 Bausch Health Business Overview
11.2.3 Bausch Health Rx Irritable Bowel Syndrome (IBS) Drugs Introduction
11.2.4 Bausch Health Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024)
11.2.5 Bausch Health Recent Development
11.3 Takeda
11.3.1 Takeda Company Detail
11.3.2 Takeda Business Overview
11.3.3 Takeda Rx Irritable Bowel Syndrome (IBS) Drugs Introduction
11.3.4 Takeda Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024)
11.3.5 Takeda Recent Development
11.4 Sebela Pharmaceuticals
11.4.1 Sebela Pharmaceuticals Company Detail
11.4.2 Sebela Pharmaceuticals Business Overview
11.4.3 Sebela Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Introduction
11.4.4 Sebela Pharmaceuticals Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024)
11.4.5 Sebela Pharmaceuticals Recent Development
11.5 Allergan
11.5.1 Allergan Company Detail
11.5.2 Allergan Business Overview
11.5.3 Allergan Rx Irritable Bowel Syndrome (IBS) Drugs Introduction
11.5.4 Allergan Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024)
11.5.5 Allergan Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of IBS-D Drugs
Table 3. Key Players of IBS-C Drugs
Table 4. Key Players of Others
Table 5. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Region (2019-2024)
Table 9. Global Rx Irritable Bowel Syndrome (IBS) Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Region (2025-2030)
Table 11. Rx Irritable Bowel Syndrome (IBS) Drugs Market Trends
Table 12. Rx Irritable Bowel Syndrome (IBS) Drugs Market Drivers
Table 13. Rx Irritable Bowel Syndrome (IBS) Drugs Market Challenges
Table 14. Rx Irritable Bowel Syndrome (IBS) Drugs Market Restraints
Table 15. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Players (2019-2024)
Table 17. Global Top Rx Irritable Bowel Syndrome (IBS) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs as of 2023)
Table 18. Ranking of Global Top Rx Irritable Bowel Syndrome (IBS) Drugs Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Rx Irritable Bowel Syndrome (IBS) Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Rx Irritable Bowel Syndrome (IBS) Drugs Product Solution and Service
Table 22. Date of Enter into Rx Irritable Bowel Syndrome (IBS) Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Type (2019-2024)
Table 26. Global Rx Irritable Bowel Syndrome (IBS) Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Type (2025-2030)
Table 28. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Application (2019-2024)
Table 30. Global Rx Irritable Bowel Syndrome (IBS) Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Rx Irritable Bowel Syndrome (IBS) Drugs Revenue Market Share by Application (2025-2030)
Table 32. North America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 47. Ironwood Pharmaceuticals Company Detail
Table 48. Ironwood Pharmaceuticals Business Overview
Table 49. Ironwood Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Product
Table 50. Ironwood Pharmaceuticals Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024) & (US$ Million)
Table 51. Ironwood Pharmaceuticals Recent Development
Table 52. Bausch Health Company Detail
Table 53. Bausch Health Business Overview
Table 54. Bausch Health Rx Irritable Bowel Syndrome (IBS) Drugs Product
Table 55. Bausch Health Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024) & (US$ Million)
Table 56. Bausch Health Recent Development
Table 57. Takeda Company Detail
Table 58. Takeda Business Overview
Table 59. Takeda Rx Irritable Bowel Syndrome (IBS) Drugs Product
Table 60. Takeda Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024) & (US$ Million)
Table 61. Takeda Recent Development
Table 62. Sebela Pharmaceuticals Company Detail
Table 63. Sebela Pharmaceuticals Business Overview
Table 64. Sebela Pharmaceuticals Rx Irritable Bowel Syndrome (IBS) Drugs Product
Table 65. Sebela Pharmaceuticals Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024) & (US$ Million)
Table 66. Sebela Pharmaceuticals Recent Development
Table 67. Allergan Company Detail
Table 68. Allergan Business Overview
Table 69. Allergan Rx Irritable Bowel Syndrome (IBS) Drugs Product
Table 70. Allergan Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024) & (US$ Million)
Table 71. Allergan Recent Development
Table 72. Research Programs/Design for This Report
Table 73. Key Data Information from Secondary Sources
Table 74. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Type: 2023 VS 2030
Figure 3. IBS-D Drugs Features
Figure 4. IBS-C Drugs Features
Figure 5. Others Features
Figure 6. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Application: 2023 VS 2030
Figure 8. Women Case Studies
Figure 9. Men Case Studies
Figure 10. Rx Irritable Bowel Syndrome (IBS) Drugs Report Years Considered
Figure 11. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Region: 2023 VS 2030
Figure 14. Global Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Players in 2023
Figure 15. Global Top Rx Irritable Bowel Syndrome (IBS) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rx Irritable Bowel Syndrome (IBS) Drugs as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Rx Irritable Bowel Syndrome (IBS) Drugs Revenue in 2023
Figure 17. North America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Country (2019-2030)
Figure 19. United States Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Country (2019-2030)
Figure 23. Germany Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Region (2019-2030)
Figure 31. China Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Country (2019-2030)
Figure 39. Mexico Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Rx Irritable Bowel Syndrome (IBS) Drugs Market Share by Country (2019-2030)
Figure 43. Turkey Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Rx Irritable Bowel Syndrome (IBS) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Ironwood Pharmaceuticals Revenue Growth Rate in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024)
Figure 46. Bausch Health Revenue Growth Rate in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024)
Figure 47. Takeda Revenue Growth Rate in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024)
Figure 48. Sebela Pharmaceuticals Revenue Growth Rate in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024)
Figure 49. Allergan Revenue Growth Rate in Rx Irritable Bowel Syndrome (IBS) Drugs Business (2019-2024)
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
